Data show high levels of short interest in 10 stocks, including Avis Budget, RH, Lucid and CleanSpar

Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names whe

Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines

BEAM-302 is being evaluated in a Phase 1/2, open-label, dose exploration and dose expansion clinical

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.91) per share which beat the analys

Jim Cramer discussed various stocks on Mad Money Lightning Round. He expressed concerns about Ondas

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acq

Prestigious Publication Reinforces risto-cel's Durable, Differentiated Clinical Data for the Tre

Citigroup analyst Samantha Semenkow maintains Beam Therapeutics (NASDAQ:BEAM) with a Buy and rais

Beam Therapeutics shares rise after BEAM-302 trial data show sustained AAT levels above threshold, s

Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patient

Termination of License Agreement with Bio Palette Co., Ltd. – Activation of Standby License from Kob

RBC Capital analyst Luca Issi maintains Beam Therapeutics (NASDAQ:BEAM) with a Sector Perform and

Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform an

Beam Therapeutics (NASDAQ: BEAM) shares are rising Tuesday after the company reported quarterly resu

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(0.10) per share which beat the analys

Canaccord Genuity analyst Whitney Ijem initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with

Bernstein analyst William Pickering maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform a

Beam Therapeutics shares are popping on Monday after the company laid out a series of pipeline updat

Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 An

UBS analyst Michael Yee initiates coverage on Beam Therapeutics (NASDAQ:BEAM) with a Neutral rati

The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 wil

Updated Data from 31 Adult and Adolescent SCD Patients Treated with risto-cel (Formerly BEAM-101) Sh

Evercore ISI Group analyst Cory Kasimov initiates coverage on Beam Therapeutics (NASDAQ:BEAM) wit

Cathie Wood-led Ark Invest purchased shares in Bullish, a crypto exchange backed by Peter Thiel, thr

Beam Therapeutics (NASDAQ:BEAM) reported quarterly losses of $(1.10) per share which missed the anal

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicine

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) wi

Jim Cramer recommends buying Affirm Holdings (AFRM) on CNBC's Mad Money Lightning Round. Analyst

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potenti

Gainers

  On Tuesday, 647 companies set new 52-week lows.

  During Monday's session, 201 stocks hit new 52-week lows.

  During Tuesday's trading, 188 companies set new 52-week lows.

  During Thursday's session, 92 stocks hit new 52-week lows.

  During Wednesday's trading, 103 companies set new 52-week lows.